enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Endo International - Wikipedia

    en.wikipedia.org/wiki/Endo_International

    Endo is one of the companies named in lawsuits by the states of Ohio, [42] Missouri and Mississippi [43] as responsible for the US opioid epidemic. Its 10-K statement indicates that a majority of the company's US revenue in 2016 was derived from the sale of prescription pain killers, predominantly opioids. [44]

  3. Consulting firm McKinsey to pay $650 million to resolve US ...

    www.aol.com/news/consulting-firm-mckinsey-pay...

    BOSTON (Reuters) -McKinsey & Co has agreed to pay $650 million to resolve a U.S. Department of Justice investigation into the consulting firm's work advising opioid manufacturer OxyContin maker ...

  4. List of Schedule II controlled substances (U.S.) - Wikipedia

    en.wikipedia.org/wiki/List_of_Schedule_II...

    This is the list of Schedule II controlled substances in the United States as defined by the ... opiate Codeine [2] 9334 opiate Dihydroetorphine [3] 9190 opiate ...

  5. Chattem - Wikipedia

    en.wikipedia.org/wiki/Chattem

    The company incorporated in 1909 and has remained in Chattanooga, Tennessee, to this day. During World War II , the Chattanooga Medicine Company turned into a major supplier of K-Rations to the US Army , producing 34 million rations from 1942 to 1945, earning 5 "E" Awards for support of war efforts.

  6. McKinsey & Company agrees to pay $650M for helping ... - AOL

    www.aol.com/mckinsey-company-agrees-pay-650...

    McKinsey & Company consulting firm has agreed to pay $650 million to settle a federal investigation into its work to help opioids manufacturer Purdue Pharma boost the sales of the highly addictive ...

  7. McKinsey to pay $650 million after advising opioid maker on ...

    www.aol.com/mckinsey-pay-650-million-advising...

    Global consulting firm McKinsey & Company agreed Friday to pay $650 million to resolve criminal and civil investigations into the advice it provided to opioids manufacturer Purdue Pharma.

  8. Titan Pharmaceuticals - Wikipedia

    en.wikipedia.org/wiki/Titan_Pharmaceuticals

    Titan's principal asset is Probuphine, [5] [6] a slow-release implant formulation of buprenorphine [7] for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016. [8] It was licensed to Braeburn Pharmaceuticals for marketing and commercialization. [6]

  9. DOJ files complaint against CVS for facilitating unlawful ...

    lite.aol.com/pf/story/0001/20241218/b402388119be...

    Among the unlawful prescriptions that CVS allegedly filled from Oct. 17, 2013, to the present were for dangerous and excessive quantities of opioids, early fills of opioids, and “trinity” prescriptions — a dangerous combination of drugs made up of an opioid, a benzodiazepine and a muscle relaxant, according to prosecutors.